{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:00:47Z","timestamp":1761541247452,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T00:00:00Z","timestamp":1667692800000},"content-version":"vor","delay-in-days":2623,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P01 HL-74124"],"award-info":[{"award-number":["P01 HL-74124"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1111\/jth.13059","type":"journal-article","created":{"date-parts":[[2015,7,17]],"date-time":"2015-07-17T10:07:49Z","timestamp":1437127669000},"page":"1694-1698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen\u2010like FXaI16L"],"prefix":"10.1016","volume":"13","author":[{"given":"L.A.","family":"George","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.K.","family":"Thalji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.J.","family":"Raffini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.A.","family":"Gimotty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.M.","family":"Camire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2006","series-title":"Hemostasis and Thrombosis: Basic Principles and Clinical Practice\u2010Overview of Inherited Hemorrhagic Disorders","author":"Roberts","key":"10.1111\/jth.13059_bb0010"},{"key":"10.1111\/jth.13059_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V76.1.1.1","article-title":"Surface dependent reactions of the vitamin K\u2010dependent enzyme complexes","volume":"76","author":"Mann","year":"1990","journal-title":"Blood"},{"key":"10.1111\/jth.13059_bb0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2516.2008.01708.x","article-title":"Back to the future: a recent history of haemophilia treatment","volume":"14","author":"Mannucci","year":"2008","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13059_bb0025","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJM199012273232604","article-title":"Human recombinant DNA\u2010derived antihemophilia factor (Factor VIII) in the treatment of hemophilia A","volume":"323","author":"Schwartz","year":"1990","journal-title":"NEJM"},{"key":"10.1111\/jth.13059_bb0030","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/pbc.24338","article-title":"Inhibitors in childhood hemophilia A: genetic and treatment\u2010related risk factors for the development and eradication","volume":"60","author":"DiMichele","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1111\/jth.13059_bb0035","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2141.2007.06657.x","article-title":"Inhibitor development in haemophilia B: an orphan disease in need of attention","volume":"138","author":"DiMichele","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.13059_bb0040","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jbiotec.2006.03.042","article-title":"Mechanism of action, development and clinical experience of recombinant FVIIa","volume":"124","author":"Hedner","year":"2006","journal-title":"J Biotechnol"},{"key":"10.1111\/jth.13059_bb0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2004.00934.x","article-title":"FEIBA: mode of action","volume":"10","author":"Turecek","year":"2004","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13059_bb0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2008.01931.x","article-title":"Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors","volume":"15","author":"Berntorp","year":"2009","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13059_bb0055","doi-asserted-by":"crossref","first-page":"78732","DOI":"10.1371\/journal.pone.0078732","article-title":"The effect of factor VIII deficiencies and replacement and bypass therapies on thrombus formation under venous flow conditions in microfluidic and computational models","volume":"13","author":"Onasoga\u2010Jarvis","year":"2013","journal-title":"PLoS One"},{"key":"10.1111\/jth.13059_bb0060","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2516.2010.02257.x","article-title":"Health economics in haemophilia: a review from the clinician's perspective","volume":"16","author":"Escobar","year":"2010","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13059_bb0065","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1538-7836.2004.00759.x","article-title":"Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors","volume":"2","author":"Abshire","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13059_bb0070","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2141.2011.08854.x","article-title":"Parallel use of by\u2010passing agents in haemophilia with inhibitors: a critical review","volume":"155","author":"Ingerslev","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.13059_bb0075","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1172\/JCI111648","article-title":"Studies of Factors V and VIII: C in an animal model of disseminated intravascular coagulation","volume":"74","author":"Giles","year":"1984","journal-title":"J Clin Invest"},{"key":"10.1111\/jth.13059_bb0080","first-page":"491","article-title":"A combination of factor Xa and phosphatidylcholine\u2010phosphatidylserine vesicles bypasses factor VIII in\u00a0vivo","volume":"69","author":"Giles","year":"1988","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.13059_bb0085","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1016\/S0021-9258(17)39811-3","article-title":"Inhibition of human activated Factor X by antithrombin III and alpha 1\u2010proteinase inhibitor in human plasma","volume":"259","author":"Gitel","year":"1984","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.13059_bb0090","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1002\/j.1460-2075.1989.tb08511.x","article-title":"The refined 1.9 A crystal structure of human alpha\u2010thrombin: interaction with D\u2010Phe\u2010Pro\u2010Arg chloromethylketone and significance of the Tyr\u2010Pro\u2010Pro\u2010Trp insertion segment","volume":"8","author":"Bode","year":"1989","journal-title":"EMBO J"},{"key":"10.1111\/jth.13059_bb0095","doi-asserted-by":"crossref","first-page":"18627","DOI":"10.1074\/jbc.M802205200","article-title":"The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly","volume":"283","author":"Toso","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.13059_bb0100","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood-2010-08-300756","article-title":"Zymogen\u2010like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in\u00a0vitro","volume":"117","author":"Bunce","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.13059_bb0105","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nbt.1995","article-title":"A zymogen\u2010like factor Xa variant corrects the coagulation defect in hemophilia","volume":"29","author":"Ivanciu","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1111\/jth.13059_bb0110","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/01.mbc.0000169225.31173.19","article-title":"Multi\u2010centre investigation of reference ranges for ROTEM thromboelastometry","volume":"16","author":"Lang","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.13059_bb0115","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/bja\/aeq258","article-title":"Thromboelastometry (ROTEM\u00ae) in\u00a0children: age\u2010related reference ranges and correlations with\u00a0standard coagulation tests","volume":"105","author":"Oswald","year":"2010","journal-title":"Br J Anaesth"},{"key":"10.1111\/jth.13059_bb0120","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1182\/blood-2012-08-378935","article-title":"Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future prospects","volume":"121","author":"Young","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.13059_bb0125","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2516.2009.02165.x","article-title":"Comparison of kaolin and tissue factor activated thromboelastography in haemophilia","volume":"16","author":"Young","year":"2010","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13059_bb0130","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.thromres.2010.05.008","article-title":"Optimizing thromboelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven) therapy in haemophilia A patients","volume":"126","author":"Viuff","year":"2010","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13059_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tmrv.2011.07.005","article-title":"Principles and practice of thromboelastography in clinical coagulation management and transfusion practice","volume":"26","author":"Bollinger","year":"2012","journal-title":"Transfus Med Rev"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13059","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13059","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622034493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622034493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.13059\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:11:09Z","timestamp":1761534669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622034493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S1538783622034493"],"URL":"https:\/\/doi.org\/10.1111\/jth.13059","relation":{},"ISSN":["1538-7836"],"issn-type":[{"type":"print","value":"1538-7836"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen\u2010like FXaI16L","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.13059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}